Frecuencia y características de la hipertensión arterial en pacientes con lupus eritematoso sistémico
DOI:
https://doi.org/10.46296/gt.v6i12.0114Palabras clave:
Lupus, hipertensión arterial, riesgo cardiovascularResumen
Introducción: La hipertensión arterial confiere un importante incremento del riesgo cardiovascular en pacientes con lupus. Objetivos: Caracterizar la hipertensión arterial y factores asociados en pacientes con lupus. Métodos: Se realizó un estudio observacional descriptivo de corte transversal que incluyó 293 pacientes con lupus eritematoso sistémico atendidos en el servició de Reumatología del Hospital Hermanos Amejeiras en el periodo correspondiente a enero 2005 y junio de 2022. Resultados: La frecuencia de HTA fue del 46,4%. El medicamento más empleado para el control de la presión arterial fueron los diuréticos. En el análisis multivariado, las variables que mostraron asociación significativa e independiente con la HTA fueron el color de la piel, el alcoholismo, la ausencia de comorbilidades, el lupus bulloso, la sinovitis, la mononeuropatía, los niveles de Anti-DNAds y Anti-SM, la hipocomplementemia y el daño de la enfermedad. De todas estas variables, las que mostraron una mayor fuerza de asociación fueron el color de la piel, los niveles de Anti-DNAds y Anti-SM, así como el daño de la enfermedad. Conclusiones: El color de piel no blanco, la positividad al Anti-DNAds y la presencia de daño de la enfermedad son las variables que con mayor probabilidad se relacionan con la hipertensión arterial en pacientes con lupus.
Palabras claves: Lupus, hipertensión arterial, riesgo cardiovascular.
Abstract
Background: High blood pressure confers a significant increase in cardiovascular risk in patients with lupus. Objectives: To characterize arterial hypertension and associated factors in patients with lupus. Methods: A cross-sectional descriptive observational study was conducted which included 293 patients with systemic lupus erythematosus assisted at Hermanos Amejeiras Hospital between January 2005 and June 2022. Results: Prevalence of arterial hypertension was 46.4%. The most used medication for blood pressure control was diuretics. In multivariate analysis, skin color, alcoholism, absence of comorbidities, lupus bullosus, synovitis, mononeuropathy, levels of Anti-DNAds and Anti-SM, hypocomplementemia and disease damage were the variables that showed a significant and independent association with hypertension. The variables with greater odds in relation to high blood pressure were skin color, Anti-DNAds and Anti-SM levels, as well as disease damage. Conclusions: Non-white skin color, positivity to Anti-DNAds and the presence of disease damage are the variables that are most likely to be related to high blood pressure in patients with lupus.
Keywords: Lupus, arterial hypertension, cardiovascular risk.
Información del manuscrito:
Fecha de recepción: 11 de abril de 2023.
Fecha de aceptación: 29 de junio de 2023.
Fecha de publicación: 10 de julio de 2023.
Descargas
Citas
Kostopoulou M, Nikolopoulos D, Parodis I, Bertsias G. Cardiovascular disease in systemic lupus erythematosus: recent data on epidemiology, risk factors and prevention. Current Vascular Pharmacology [Internet]. 2020 [citado agosto 2022]; 18(6):549-65. Disponible en: https://europepmc.org/article/med/31880245
Saito M, Yajima N, Yanai R, Tsubokura Y, Ichinose K, Yoshimi R, et al. Prevalence and treatment conditions for hypertension and dyslipidaemia complicated with systemic lupus erythematosus: A multi-centre cross-sectional study. Lupus [Internet]. 2021 [citado agosto 2022]; 30(7):1146-53. Disponible en: https://pubmed.ncbi.nlm.nih.gov/33794706/
Tselios K, Koumaras C, Urowitz MB, Gladman DD. Do current arterial hypertension treatment guidelines apply to systemic lupus erythematosus patients? A critical appraisal. In Seminars in arthritis and rheumatism [Internet]. 2014 [citado agosto 2022]; 43(4):521-5. Disponible en: https://www.sciencedirect.com/science/article/pii/ S0049017213001558
Sabio J, Vargas-Hitos J, Navarrete-Navarrete N, Mediavilla J, Jimenez-Jaimez J, Diaz-Chamorro A, et al. Prevalence of and factors associated with hypertension in young and old women with systemic lupus erythematosus. J Rheumatol [Internet]. 2011 [citado agosto 2022]; 38:1026-32. Disponible en: https://www.jrheum.org/content/38/ 6/1026.short
Taylor EB, Ryan MJ. Understanding mechanisms of hypertension in systemic lupus erythematosus. Therapeutic advances in cardiovascular disease [Internet]. 2017 [citado agosto 2022]; 11(1):20-32. Disponible en: https://europepmc.org/article/pmc/pmc5065379#free-full-text
Munguia-Realpozo P, Mendoza-Pinto C, Benito CS, Escarcega RO, Garcia-Carrasco M, Martinez SM, et al. Systemic lupus erythematosus and hypertension. Autoimmunity Reviews [Internet]. 2019 [citado agosto 2022]; 18(10):102371. Disponible en: https://www.sciencedirect.com/science/article/pii/S1568997219301715
Rachdi I, Daoud F, Zoubeidi H, Somai M, Fekih Y, Dhaou BB, et al. Arterial Hypertension in Systemic Lupus Erythematosus: About 40 Cases. Saudi Journal of Kidney Diseases and Transplantation [Internet]. 2020 [citado agosto 2022]; 31(4), 814. Disponible en: https://europepmc.org/article/med/32801242
Barbhaiya M, Feldman CH, Guan H, Gómez-Puerta JA, Fischer MA, Solomon DH, et al. Race/Ethnicity and Cardiovascular Events among Patients with Systemic Lupus Erythematosus. Arthritis & rheumatology (Hoboken, NJ) [Internet]. 2017 [citado agosto 2022]; 69(9):1823-31. Disponible en: https://europepmc.org/article/pmc/pmc6143392
Sabio J, Vargas-Hitos J, Navarrete-Navarrete N, Mediavilla J, Jimenez-Jaimez J, Diaz-Chamorro A, et al. Prevalence of and factors associated with hypertension in young and old women with systemic lupus erythematosus. J Rheumatol [Internet]. 2011 [citado agosto 2022]; 38:1026-32. Disponible en: https://www.jrheum.org/content/38/ 6/1026.short
Gandelman JS, Khan OA, Shuey MM, Neal JE, McNeer E, Dickson A, et al. Increased incidence of resistant hypertension in patients with systemic lupus erythematosus: a retrospective cohort study. Arthritis care & research [Internet]. 2020 [citado agosto 2022]; 72(4):534-43. Disponible en: https://europepmc.org/articles/pmc6745299/bin/nihms1016775-supplement-supp_info.docx
Ortega LM, Sedki E, Nayer A. Hypertension in the African American population: A succinct look at its epidemiology, pathogenesis, and therapy. Nefrología: publicación oficial de la Sociedad Española Nefrología [Internet]. 2015 [citado agosto 2022]; 35(2):139-45. Disponible en: https://www.sciencedirect.com/science/article/pii/S02 11699515000260
Hernández RR, Rodríguez AA., Báster JL, Martínez MD, Miguel-Soca PE, Anido YC. Factores de riesgo asociados a hipertensión arterial en pacientes con lupus eritematoso sistémico. Holguín, Cuba. Revista Habanera de Ciencias Médicas [Internet]. 2017 [citado agosto 2022]; 16(6):1086-99. Disponible en: https://www.medigraphic.com/cgi-bin/new/resumen.cgi?IDARTICULO=79568
Stojan G, Magder LS, Petri M. Blood pressure variability and age-related blood pressure patterns in systemic lupus erythematosus. The Journal of rheumatology [Internet]. 2020 [citado agosto 2022]; 47(3):387-93. Disponible en: https://www.jrheum.org/content/47/3/387.abstract
Du T, Pang H, Ding F, Ye Y, Li M, Yang X, et al. Reduction in SLEDAI is associated with improved arterial stiffness in systemic lupus erythematosus. Medicine [Internet]. 2020 [citado agosto 2022]; 99(47). Disponible en: https://europepmc.org/articles/pmc7676556/bin/medi-99-e23184-s002.docx
Ming Ding F, Li M, Yang X, Ye Y, Kang L, Pang H, et al. Accelerated age-related arterial stiffness in systemic lupus erythematosus patients. JCR [Internet]. 2016 [citado agosto 2022]; 22:426-33. Disponible en: https://journals.lww.com/jclinrheum/Fulltext/2016/12000/Accelerated_Age_Related_Arterial_Stiffness_in.5.aspx
Shang Q, Tam LS, Li EK, Yip GWK, Yu CM. Increased arterial stiffness correlated with disease activity in systemic lupus erythematosus. Lupus [Internet]. 2008 [citado agosto 2022]; 17:1096-102. Disponible en: https://journals.sagepub.com/doi/abs/10.1177/0961203308092160
Drosos GC, Vedder D, Houben E, Boekel L, Atzeni F, Badreh S, et al. EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. Annals of the rheumatic diseases [Internet]. 2022 [citado julio 2022]; 81(6):768-79. Disponible en: https://ard.bmj.com/content/81/6/768.abstract
Porta S, Danza A, Arias Saavedra, M., Carlomagno A, Goizueta MC, Vivero F, Ruiz-Irastorza G. Glucocorticoids in systemic lupus erythematosus. Ten questions and some issues. Journal of Clinical Medicine [Internet]. 2020 [citado agosto 2022]; 9(9), 2709. Disponible en: https://www.mdpi.com/804866
Reiss AB, Jacob B, Ahmed S, Carsons SE, DeLeon J. Understanding accelerated atherosclerosis in systemic lupus erythematosus: toward better treatment and prevention. Inflammation [Internet]. 2021 [citado agosto 2022]; 44(5):1663-82. Disponible en: https://link.springer.com/article/10.1007/s10753-021-01455-6
Floris A, Piga M, Mangoni AA, Bortoluzzi A, Erre GL, Cauli A. Protective Effects of Hydroxychloroquine against Accelerated Atherosclerosis in Systemic Lupus Erythematosus. Mediators of Inflammation [Internet]. 2018 [citado agosto 2022]; 3424136-3424136. Disponible en: https://www.hindawi.com/journals/mi/2018/3424136/
McMahon M, Skaggs B, Grossman J, Wong WK, Sahakian L, Chen W, Hahn B. Comparison of PREDICTS atherosclerosis biomarker changes after initiation of new treatments in patients with SLE. Lupus Science & Medicine [Internet]. 2019 [citado agosto 2022]; 6(1), e000321. Disponible en: https://lupus.bmj.com/content/6/1/e000321.abstract
Zhao TX, Aetesam-Ur-Rahman M, Sage AP, Victor S, Kurian R, Fielding S, et al. Rituximab in patients with acute ST-elevation myocardial infarction: an experimental medicine safety study. Cardiovascular research [Internet]. 2022 [citado agosto 2022]; 118(3):872-82. Disponible en: https://academic.oup.com/cardiovascres/article-abstract/118/3/872/ 6203810
Publicado
Cómo citar
Número
Sección
Derechos de autor 2023 Revista Científica Arbitrada en Investigaciones de la Salud GESTAR. ISSN: 2737-6273.

Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.